Apricus Biosciences Inc. (Nasdaq: APRI) and the Food and Drug Administration agreed on the design of a clinical trial for the advanced, inoperable liver cancer treatment PrevOnco sending the stock price soaring $0.65 to close at $3.35.
Apricus Biosciences And FDA Agree On Trial Design
November 22, 2010 at 17:53 PM EST
